Christian democracy

Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Retrieved on: 
Thursday, September 22, 2022
Odds, Central nervous system, Neuroblastoma, Safety, Radiation, Osteosarcoma, COVID-19, Twitter, Risk, FDA, HGG, Food, WM, Multiple myeloma, Lymphoma, Sarcoma, Neoplasm, Part, LinkedIn, Population, MM, European Commission, News, U.S. Securities and Exchange Commission, Survival, Patient, Exchange, Cancer, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, B-cell lymphoma, CEO, Rhabdomyosarcoma, Christian democracy, Regulation, Progression-free survival, Brain, Diffuse intrinsic pontine glioma, Pediatric ependymoma, PDC, NASDAQ, Collection, Astrocytoma, Research, Security (finance), GLOBE, Glioblastoma, Marketing, Drug discovery, DLBCL, National Institute, Pharmaceutical industry, Facebook

The funding allows for an expansion from the Part 1a into the Part 1b portion of the companys ongoing Phase 1 pediatric study.

Key Points: 
  • The funding allows for an expansion from the Part 1a into the Part 1b portion of the companys ongoing Phase 1 pediatric study.
  • The currently ongoing Phase 1a is designed to determine the safety, tolerability, and initial efficacy of iopofosine in pediatric brain tumors whereas the Phase 1b is designed to identify the dose and dosing regimen that results in optimal efficacy.
  • Unfortunately, patients with HGGs often have very poor prognoses, with limited treatment options, said James Caruso, president and CEO of Cellectar.
  • The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

Best-Selling Workforce-Focused Authors Keynote Chief Learning Officer Symposium

Retrieved on: 
Wednesday, August 31, 2022
Workforce, Research, Oliver Cromwell, CLO, Sullivan & Cromwell, Learning, Courage, Intelligence, Clos, Goal, L&D, GLOBE, Symposium, Leadership, Workplace, Walmart, Growth, Industry, Christian democracy, Management

CHICAGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Chief Learning Officer (CLO),a publication serving C-suite and senior-level learning and development professionals, has announced the keynote lineup for its 2022 Virtual CLO Symposium, taking place Oct. 18-20.

Key Points: 
  • CHICAGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Chief Learning Officer (CLO),a publication serving C-suite and senior-level learning and development professionals, has announced the keynote lineup for its 2022 Virtual CLO Symposium, taking place Oct. 18-20.
  • His presentation will take place on day one of the Symposium, Tuesday, Oct. 18.
  • "Our keynote speakers set the stage for the overall energy of each day, and we are honored to welcome three exceptionally inspiring individuals who all bring vastly different perspectives on today's transformative times," said Ashley St. John, editor-in-chief of Chief Learning Officer.
  • Chief Learning Officer is dedicated to serving as a platform and vehicle for C-suite and senior-level learning and development professionals to connect and advance in the profession and their personal careers.

Cellectar Reports Financial Results for Second Quarter 2022

Retrieved on: 
Friday, August 5, 2022
FDA, Hand, Lymphoma, Sarcoma, Risk, CEO, GLOBE, R, Neuroblastoma, Cancer, Leadership, PDC, Security (finance), Research, Marketing, Patient, Drug discovery, COVID-19, WM, Twitter, U.S. Securities and Exchange Commission, Safety, G&A, State Administrative Expenses, NASDAQ, Exchange, Cash, News, LinkedIn, Development, Christian democracy, Brain, Regulation, Fine chemical, Pharmaceutical industry, Facebook

FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June30, 2022.

Key Points: 
  • FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June30, 2022.
  • Net cash used in operating activities during the six months ended June30, 2022 was approximately $10.8 million.
  • The company believes its cash on hand is adequate to fund basic budgeted operations into the third quarter of 2023.
  • For the six months ended June30, 2022, R&D expense was approximately $8.4 million, while the comparable period in 2021 was $9.3 million.

Cellectar Announces Stock Consolidation

Retrieved on: 
Thursday, July 21, 2022
Transfer, Shareholder, Exchange, GLOBE, WM, Christian democracy, Twitter, Regulation, Drug discovery, CUSIP, Sarcoma, Neuroblastoma, Research, Indian stock exchange, PDC, Marketing, Lymphoma, Risk, Safety, COVID-19, Bangladesh Securities and Exchange Commission, Cancer, News, Brain, FDA, Company, Security (finance), Patient, LinkedIn, Nasdaq, Certificate of incorporation, Pharmaceutical industry, Facebook

The Company has amended its Certificate of Incorporation to effect the stock consolidation.

Key Points: 
  • The Company has amended its Certificate of Incorporation to effect the stock consolidation.
  • Proportionate voting rights and other rights of common stockholders will not be affected by the reverse stock split, other than as a result of the cashing out of fractional shares.
  • Please direct any questions you might have regarding the reverse split to your broker or the companys stock transfer agent, American Stock Transfer & Trust Company, by calling (800) 937-5449 (domestic), or (718) 921-8317 (international).
  • Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer.

Theralase Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, June 28, 2022
TSX Venture Exchange, Patient, PDC, Research, TSX, Trial of the century, MAK Technologies, Inc., Non-small-cell lung carcinoma, Studie II, GLOBE, Mechanism of action, COVID-19, Cancer, Company, AES, Health Canada, Bacteria, Risk, IP, Reactive oxygen species, Technology, Singlet oxygen, Virus, Safety, Incidence, CR, TLT, Time, Intellectual property, Patent, News, Glioblastoma, Recurrence, NMIBC, Interim, Christian democracy, Pharmaceutical industry

Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).

Key Points: 
  • Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).
  • The patent advances Theralases intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (ACT) platform.
  • This patent further strengthens the extensive portfolio of patents already held by Theralase.
  • Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer (CEO) and Chief Scientific Officer (CSO), Theralase stated that, This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally.

Soricimed Appoints Nationally Recognized Scientific and Academic Leader, Dr. Rodney Ouellette, to its Scientific Advisory Board

Retrieved on: 
Thursday, June 2, 2022
Digital health, Leadership, PHD, Christian democracy, Sister republic, Company, Molecular and Cellular Biology, Research, Science, S-1 Executive Committee, Doctor of Philosophy, Biomedical Research, Food, Committee, New Brunswick Innovation Foundation, New, Executive Committee, Paralysis, Therapy, Investment, Public, ACRI, Private sector, Precision medicine, United States Air Force Scientific Advisory Board, Peptide, Prostate cancer, Health, MD, Teaching hospital, Board, SAB, Molecular genetics, Regulation of tobacco by the U.S. Food and Drug Administration, Biochemistry, Science Advisory Board, Family medicine, Cancer, Council, Board of directors, Pharmaceutical industry, Universitate metro station, NB

"We are honored to welcome Dr. Ouellette to our SAB," stated Robert Bruce, Chief Executive Officer of Soricimed.

Key Points: 
  • "We are honored to welcome Dr. Ouellette to our SAB," stated Robert Bruce, Chief Executive Officer of Soricimed.
  • Dr. Ouellette commented, "Soricimed's story exemplifies the translation of a biological discovery into a cancer therapeutic, which has long been a focus of mine.
  • Soricimed is a privately held clinical stage company focused primarily on the development of targeted, first-in-class cancer treatments.
  • In addition, a portfolio of targeted Peptide-drug Conjugates (PDCs) and Peptide Receptor Radionuclide Therapies (PRRTs) are in various stages of pre-clinical development.

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata

Retrieved on: 
Tuesday, May 17, 2022
Pharmaceutical, Genetics, Health, Clinical Trials, Christian democracy, Nasdaq, Degenerative disease, Patient, Â, Hair, Cell, Depression, SALT, Week, Alopecia areata, Anxiety, ILT7, Lupus erythematosus, Hair loss, Pharmaceutical industry

The primary endpoint is the percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 24.

Key Points: 
  • The primary endpoint is the percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 24.
  • This endpoint is a well-validated metric and widely utilized tool for determining the degree of hair loss and regrowth4.
  • SALT scores are measured on a scale from 1 to 100, with 1 representing no hair loss and 100 representing total hair loss.
  • Horizon is also investigating daxdilimab in systemic lupus erythematosus and plans to investigate it in dermatomyositis, discoid lupus erythematosus and lupus nephritis.

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress. Partner Menarini Group to present clinical poster on SEL24 (MEN1703)

Retrieved on: 
Thursday, May 12, 2022
WSE, Acute myeloid leukemia, Knowledge, Population, Christian democracy, NPM1, Gene, Warsaw Stock Exchange, AML, Patient, 2021 Essex County Council election, Therapy, Lymphatic system, EHA, DNMT3A, Congress, Safety, Mall of America, Cancer, Myelodysplastic syndrome, Pharmaceutical industry

KRAKOW, Poland, May 12, 2022 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that the data from the Phase 1b dose-escalation study of RVU120 (SEL120) in patients with AML or high-risk myelodysplastic syndromes (HR-MDS) and the Phase 1/2 study of SEL24 (MEN1703) in Patients with IDH1/2-Mutated AML will be presented at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, June 9-17 in Vienna, Austria and online.

Key Points: 
  • Notably, our translational data confirm the proposed MoA in a molecularly-defined subset ofpatients with DNMT3A and NPM1 mutations.
  • Based on the encouraging data, we plan to further advance the clinical development of RVU120 in both biomarker-driven AML patients as well as in theunselected broader AML population.
  • We are also proud that the SEL24 (MEN1703) program, developed in collaboration with our partner Menarini, is making progress in the clinic.
  • Ryvu is listed on the main market of the Warsaw Stock Exchange and is a component of sWIG80 index.

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, U.S. Securities and Exchange Commission, Drug discovery, Mission statement, DMC, Multiple myeloma, Twitter, Christian democracy, NASDAQ, GLOBE, PDC, Lymphoma, Development, Travel, Safety, Research, Neuroblastoma, State Administrative Expenses, Patient, Hand, Security (finance), Review, FDA, Cancer, Sarcoma, Exchange, Marketing, LinkedIn, Cash, CEO, News, G&A, Regulation, Brain, Risk, Pharmaceutical industry, WM, Facebook

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • Net cash used in operating activities during the three months ended March 31, 2022 was approximately $5.0 million.
  • The company believes its cash on hand is adequate to fund basic budgeted operations for at least 12 months from the filing of the first quarter 2022 financial statements.
  • These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

PACCAR Achieves Excellent Quarterly Revenues and Profits

Retrieved on: 
Tuesday, April 26, 2022
Automotive Manufacturing, Aftermarket, Automotive, Manufacturing, Other Transport, Trucking, Transport, Other Automotive, General Automotive, Logistics, Supply Chain Management, Fleet Management, Capital expenditure, 579, Webcast, Christian democracy, Nasdaq, PFS, Population, U.S. Securities and Exchange Commission, Security (finance), Research, Technology, Interest, DAF XF, PDC, Private Securities Litigation Reform Act, PCAR, Investment, Uncertainty, PACCAR, Efficiency, DAF, ADAS, TRP, Semiconductor, Income, XG, XF, Multimedia, Industry, Heavy equipment, Taxicab, Video game, Renewable energy, Commercial property, Rail freight transport, Kenworth, Amazon, Peterbilt

PACCAR reported excellent revenues and net income for the first quarter of 2022, said Preston Feight, chief executive officer.

Key Points: 
  • PACCAR reported excellent revenues and net income for the first quarter of 2022, said Preston Feight, chief executive officer.
  • PACCAR Parts achieved record quarterly sales and profits as its outstanding operational performance enhanced uptime for customers.
  • PACCAR Financial Services delivered record profitability due to excellent portfolio quality, strong new business volume and high used truck prices.
  • Laura Bloch, PACCAR vice president and PACCAR Parts general manager, said, Customers increased truck utilization and higher average fleet age contributed to PACCAR Parts record results.